6-(4-morpholinobenzylidene)-6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-5-one

ID: ALA5270772

Max Phase: Preclinical

Molecular Formula: C21H19NO4

Molecular Weight: 349.39

Names and Identifiers

Canonical SMILES:  O=C1/C(=C/c2ccc(N3CCOCC3)cc2)Cc2cc3c(cc21)OCO3

Standard InChI:  InChI=1S/C21H19NO4/c23-21-16(10-15-11-19-20(12-18(15)21)26-13-25-19)9-14-1-3-17(4-2-14)22-5-7-24-8-6-22/h1-4,9,11-12H,5-8,10,13H2/b16-9+

Standard InChI Key:  ZZJWKSYFNZCSRW-CXUHLZMHSA-N

Molfile:  

 
     RDKit          2D

 26 30  0  0  0  0  0  0  0  0999 V2000
   -2.5663    1.8231    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8518    2.2354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1398    1.8235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1398    0.9983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8499    0.5865    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5663    0.9946    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3551    0.7433    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3551    2.0785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1298    1.4108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3542    2.0791    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3542    0.7385    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8412    1.4089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1414    2.8756    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.9550    1.4108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3676    0.6962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1928    0.6959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6035   -0.0168    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1908   -0.7317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3697   -0.7332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9532   -0.0214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6034   -1.4463    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4286   -1.4463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8412   -2.1609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4285   -2.8756    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.6034   -2.8756    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1908   -2.1609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  4  7  1  0
  3  8  1  0
  8  9  1  0
  9  7  1  0
  1 10  1  0
  6 11  1  0
 11 12  1  0
 12 10  1  0
  8 13  2  0
  9 14  2  0
 14 15  1  0
 16 15  2  0
 17 16  1  0
 18 17  2  0
 19 18  1  0
 20 19  2  0
 15 20  1  0
 18 21  1  0
 22 21  1  0
 23 22  1  0
 24 23  1  0
 25 24  1  0
 26 25  1  0
 21 26  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5270772

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 349.39

Molecular Weight (Monoisotopic): 349.1314

AlogP: 3.07

#Rotatable Bonds: 2

Polar Surface Area: 48.00

Molecular Species: NEUTRAL

HBA: 5

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 1.11

CX LogP: 3.40

CX LogD: 3.40

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.78

Np Likeness Score: -0.50

References

1. Altıntop MD, Özdemir A, Temel HE, Demir Cevizlidere B, Sever B, Kaplancıklı ZA, Akalın Çiftçi G..  (2022)  Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer.,  244  [PMID:36270087] [10.1016/j.ejmech.2022.114851]

Source

Source(1):

• Scientific Literature